Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
Célia Pedroso, Sara Vaz, Eduardo Martins Netto, Daniele Souza, Felice Deminco, Rafaela Mayoral, Eliana Menezes, Ana Patricia Amancio Da Cunha, Andres Moreira-Soto, Jan Felix Drexler, Carlos Brites
The Brazilian Journal of Infectious Diseases, doi:10.1016/j.bjid.2021.101603
Background: Over-the-counter use of ivermectin amongst other drugs as SARS-CoV-2 treatment has been increasingly common, despite the lack of evidence on its clinical efficacy. Objective: To evaluate the effect of ivermectin use on production of antibodies against SARS-CoV-2 in health care workers (HCW) diagnosed with COVID-19 and of Th1/Th2 cytokines by stimulated peripheral blood mononuclear cells of the same cohort (PBMCs). Methods: This cross-sectional study evaluated seroconversion and neutralizing antibodies production in HCW at Complexo Hospitalar Universit ario Professor Edgard Santos (Salvador, Brazil), diagnosed with COVID-19 from May to July, 2020, as well as in vitro production of antibody against SARS-CoV-2 and Th1/Th2 cytokines. Analyses were performed between December 2020 and February 2021. Participants were stratified according to the use of ivermectin (≤ 1 dose vs. multiple doses) for treatment of COVID-19. Results: 45 HCW were included (62% women). Mean age was 39 years, and disease severity was similar across groups. Neutralizing antibodies were detected less frequently in multiple doses (70%) vs. ≤ 1 dose (97%) groups, p = 0.02). PBMCs of patients in multiple doses group also were less likely to produce antibodies against SARS-CoV-2 following in vitro stimulation with purified spike protein in comparison with patients in ≤ 1 dose group (p < 0.001). PBMCs production of Th1/Th2 cytokines levels was similar across groups. Abdominal pain (15% vs 46%, p = 0.04), diarrhea (21% vs. 55%, p = 0.05) and taste perversion (0% vs. 18%, p = 0.05) were more frequently reported by participants that used multiple doses of ivermectin. Conclusions: Although there was no evidence for differential disease severity upon ivermectin use for treatment of COVID-19 it was associated with more gastro-intestinal side-effects and impairment of anti-SARS-CoV2 antibodies production, in a dose dependent manner.
References
Amadori, De Rossi, Giaquinto, Faulkner-Valle, None
El-Tahtawy, Glue, Andrews, Mardekian, Amsden, None
Gallardo, Teiti, Rochaix, Macrocyclic lactones block 205 melanoma growth, metastases development and potentiate 206 activity of anti-BRAF V600 inhibitors, Clin Skin Cancer
Gonzalez De Castro, Clarke, Al-Lazikani, Workman, None
Guzzo, Safety, tolerability, and pharmacokinetics of 225 escalating high doses of ivermectin in healthy adult subjects
Knirsch, The effect of azithromycin on ivermectin 229 pharmacokinetics − a population pharmacokinetic model
Rusconi, Santambrogio, Marco, Lack of in vitro 201 anti-gp160 antibody production is a correlate of 202 nonprogression among HIV type 1-infected individuals, AIDS
Tang, Hu, Wang, Ivermectin, a potential 213 anticancer drug derived from an antiparasitic drug, Pharmacol
Tay, Fraser, Chan, Nuclear localization of 217 dengue virus (DENV) 1-4 non-structural protein 5; protection 218 against all 4 DENV serotypes by the inhibitor Ivermectin
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, None
{ 'indexed': {'date-parts': [[2024, 5, 3]], 'date-time': '2024-05-03T11:18:39Z', 'timestamp': 1714735119618},
'reference-count': 16,
'publisher': 'Elsevier BV',
'issue': '4',
'license': [ { 'start': { 'date-parts': [[2021, 7, 1]],
'date-time': '2021-07-01T00:00:00Z',
'timestamp': 1625097600000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2021, 7, 30]],
'date-time': '2021-07-30T00:00:00Z',
'timestamp': 1627603200000},
'content-version': 'vor',
'delay-in-days': 29,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr',
'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2021, 7]]},
'DOI': '10.1016/j.bjid.2021.101603',
'type': 'journal-article',
'created': {'date-parts': [[2021, 8, 12]], 'date-time': '2021-08-12T08:14:22Z', 'timestamp': 1628756062000},
'page': '101603',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 7,
'title': 'Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care '
'workers diagnosed with COVID, in a dose-dependent response',
'prefix': '10.1016',
'volume': '25',
'author': [ {'given': 'Célia', 'family': 'Pedroso', 'sequence': 'first', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-7556-9670',
'authenticated-orcid': False,
'given': 'Sara',
'family': 'Vaz',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-1691-6761',
'authenticated-orcid': False,
'given': 'Eduardo Martins',
'family': 'Netto',
'sequence': 'additional',
'affiliation': []},
{'given': 'Daniele', 'family': 'Souza', 'sequence': 'additional', 'affiliation': []},
{'given': 'Felice', 'family': 'Deminco', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rafaela', 'family': 'Mayoral', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5700-4430',
'authenticated-orcid': False,
'given': 'Eliana',
'family': 'Menezes',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Ana Patricia Amancio',
'family': 'da Cunha',
'sequence': 'additional',
'affiliation': []},
{'given': 'Andres', 'family': 'Moreira-Soto', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jan Felix', 'family': 'Drexler', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4673-6991',
'authenticated-orcid': False,
'given': 'Carlos',
'family': 'Brites',
'sequence': 'additional',
'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.bjid.2021.101603_bib0001',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2020.104787',
'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 '
'in vitro',
'volume': '178',
'author': 'Caly',
'year': '2020',
'journal-title': 'Antiviral Res'},
{ 'issue': '3-4',
'key': '10.1016/j.bjid.2021.101603_bib0002',
'doi-asserted-by': 'crossref',
'first-page': '347',
'DOI': '10.1016/0165-2427(94)05308-F',
'article-title': 'Influence of ivermectin on cellular and humoral immune responses of '
'lambs',
'volume': '44',
'author': 'Stankiewicz',
'year': '1995',
'journal-title': 'Vet Immunol Immunopathol'},
{ 'issue': '21',
'key': '10.1016/j.bjid.2021.101603_bib0003',
'doi-asserted-by': 'crossref',
'first-page': '1966',
'DOI': '10.1016/j.lfs.2007.02.025',
'article-title': 'Effect of ivermectin on the cellular and humoral immune responses of '
'rabbits',
'volume': '80',
'author': 'Sajid',
'year': '2007',
'journal-title': 'Life Sci'},
{ 'issue': '7',
'key': '10.1016/j.bjid.2021.101603_bib0004',
'doi-asserted-by': 'crossref',
'first-page': '1478',
'DOI': '10.3201/eid2607.200841',
'article-title': 'Severe acute respiratory syndrome coronavirus 2−specific antibody '
'responses in coronavirus disease patients',
'volume': '26',
'author': 'Okba',
'year': '2020',
'journal-title': 'Emerg Infect Dis'},
{ 'key': '10.1016/j.bjid.2021.101603_bib0005',
'doi-asserted-by': 'crossref',
'unstructured': 'Persisting neutralizing activity to SARS-CoV-2 over months in sera of '
'COVID-19 patients Viruses. 2020 Dec; 12(12): 1357.Published online 2020 '
'Nov 27. doi: 10.3390/v12121357',
'DOI': '10.3390/v12121357'},
{ 'issue': '3',
'key': '10.1016/j.bjid.2021.101603_bib0006',
'article-title': 'Rapid generation of neutralizing antibody responses in COVID-19 '
'patients',
'volume': '1',
'author': 'Suthar',
'year': '2020',
'journal-title': 'Cell Rep Med'},
{ 'issue': '3',
'key': '10.1016/j.bjid.2021.101603_bib0007',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.2807/1560-7917.ES.2020.25.3.2000045',
'article-title': 'Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR',
'volume': '25',
'author': 'Corman',
'year': '2020',
'journal-title': 'Eurosurveillance'},
{ 'issue': '8590',
'key': '10.1016/j.bjid.2021.101603_bib0008',
'doi-asserted-by': 'crossref',
'first-page': '852',
'DOI': '10.1016/S0140-6736(88)91603-0',
'article-title': 'In-vitro production of HIV-specific antibody in children at risk of '
'AIDS',
'volume': '1',
'author': 'Amadori',
'year': '1988',
'journal-title': 'Lancet'},
{ 'issue': '15',
'key': '10.1016/j.bjid.2021.101603_bib0009',
'doi-asserted-by': 'crossref',
'first-page': '1341',
'DOI': '10.1089/aid.1998.14.1341',
'article-title': 'Lack of in vitro anti-gp160 antibody production is a correlate of '
'nonprogression among HIV type 1-infected individuals',
'volume': '14',
'author': 'Rusconi',
'year': '1998',
'journal-title': 'AIDS Res Hum Retroviruses'},
{ 'issue': '1',
'key': '10.1016/j.bjid.2021.101603_bib0010',
'doi-asserted-by': 'crossref',
'first-page': '4',
'DOI': '10.1016/j.clsc.2016.05.001',
'article-title': 'Macrocyclic lactones block melanoma growth, metastases development and '
'potentiate activity of anti-BRAF V600 inhibitors',
'volume': '1',
'author': 'Gallardo',
'year': '2016',
'journal-title': 'Clin Skin Cancer'},
{ 'issue': '3',
'key': '10.1016/j.bjid.2021.101603_bib0011',
'doi-asserted-by': 'crossref',
'first-page': '252',
'DOI': '10.1038/clpt.2012.237',
'article-title': 'Personalized cancer medicine: molecular diagnostics, predictive '
'biomarkers, and drug resistance',
'volume': '93',
'author': 'Gonzalez de Castro',
'year': '2013',
'journal-title': 'Clin Pharmacol Ther'},
{ 'key': '10.1016/j.bjid.2021.101603_bib0012',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.phrs.2020.105207',
'article-title': 'Ivermectin, a potential anticancer drug derived from an antiparasitic '
'drug',
'volume': '163',
'author': 'Tang',
'year': '2021',
'journal-title': 'Pharmacol Res'},
{ 'key': '10.1016/j.bjid.2021.101603_bib0013',
'doi-asserted-by': 'crossref',
'first-page': '301',
'DOI': '10.1016/j.antiviral.2013.06.002',
'article-title': 'Nuclear localization of dengue virus (DENV) 1-4 non-structural protein '
'5; protection against all 4 DENV serotypes by the inhibitor Ivermectin',
'volume': '99',
'author': 'Tay',
'year': '2013',
'journal-title': 'Antiviral Res'},
{ 'key': '10.1016/j.bjid.2021.101603_bib0014',
'doi-asserted-by': 'crossref',
'first-page': '851',
'DOI': '10.1042/BJ20120150',
'article-title': 'Ivermectin is a specific inhibitor of importin alpha/beta-mediated '
'nuclear import able to inhibit replication of HIV-1 and dengue virus',
'volume': '443',
'author': 'Wagstaff',
'year': '2012',
'journal-title': 'Biochem J'},
{ 'issue': '10',
'key': '10.1016/j.bjid.2021.101603_bib0015',
'doi-asserted-by': 'crossref',
'first-page': '1122',
'DOI': '10.1177/009127002401382731',
'article-title': 'Safety, tolerability, and pharmacokinetics of escalating high doses of '
'ivermectin in healthy adult subjects',
'volume': '42',
'author': 'Guzzo',
'year': '2002',
'journal-title': 'J Clin Pharmacol.'},
{ 'key': '10.1016/j.bjid.2021.101603_bib0016',
'doi-asserted-by': 'crossref',
'first-page': 'e236',
'DOI': '10.1371/journal.pntd.0000236',
'article-title': 'The effect of azithromycin on ivermectin pharmacokinetics – a '
'population pharmacokinetic model analysis',
'volume': '2',
'author': 'El-Tahtawy',
'year': '2008',
'journal-title': 'PLoS Negl Trop Dis'}],
'container-title': 'The Brazilian Journal of Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1413867021000726?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1413867021000726?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 9, 29]],
'date-time': '2021-09-29T05:09:22Z',
'timestamp': 1632892162000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1413867021000726'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 7]]},
'references-count': 16,
'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 7]]}},
'alternative-id': ['S1413867021000726'],
'URL': 'http://dx.doi.org/10.1016/j.bjid.2021.101603',
'relation': {},
'ISSN': ['1413-8670'],
'subject': [],
'container-title-short': 'The Brazilian Journal of Infectious Diseases',
'published': {'date-parts': [[2021, 7]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Self-prescribed Ivermectin use is associated with a lower rate of '
'seroconversion in health care workers diagnosed with COVID, in a dose-dependent '
'response',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'The Brazilian Journal of Infectious Diseases',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.bjid.2021.101603',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, '
'S.L.U.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '101603'}
